255 related articles for article (PubMed ID: 30878213)
21. [Oral calcimimetics on secondary hyperparathyroidism of uremia.].
Imanishi Y
Clin Calcium; 2017; 27(4):561-566. PubMed ID: 28336833
[TBL] [Abstract][Full Text] [Related]
22. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
23. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism.
Goodman WG; Hladik GA; Turner SA; Blaisdell PW; Goodkin DA; Liu W; Barri YM; Cohen RM; Coburn JW
J Am Soc Nephrol; 2002 Apr; 13(4):1017-1024. PubMed ID: 11912261
[TBL] [Abstract][Full Text] [Related]
24. Use of calcimimetics in children with normal kidney function.
VanSickle JS; Srivastava T; Alon US
Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
[TBL] [Abstract][Full Text] [Related]
25. Use of calcimimetics in uremic patients with secondary hyperparathyroidism: review.
Ureña P
Artif Organs; 2003 Sep; 27(9):759-64. PubMed ID: 12940896
[TBL] [Abstract][Full Text] [Related]
26. Future role of calcimimetics in end-stage renal disease.
Goodman WG; Turner SA
Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
[TBL] [Abstract][Full Text] [Related]
27. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
28. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Walter S; Baruch A; Dong J; Tomlinson JE; Alexander ST; Janes J; Hunter T; Yin Q; Maclean D; Bell G; Mendel DB; Johnson RM; Karim F
J Pharmacol Exp Ther; 2013 Aug; 346(2):229-40. PubMed ID: 23674604
[TBL] [Abstract][Full Text] [Related]
29. Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1.
Levi R; Ben-Dov IZ; Lavi-Moshayoff V; Dinur M; Martin D; Naveh-Many T; Silver J
J Am Soc Nephrol; 2006 Jan; 17(1):107-12. PubMed ID: 16291838
[TBL] [Abstract][Full Text] [Related]
30. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
31. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.
Goodman WG; Frazao JM; Goodkin DA; Turner SA; Liu W; Coburn JW
Kidney Int; 2000 Jul; 58(1):436-45. PubMed ID: 10886592
[TBL] [Abstract][Full Text] [Related]
32. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
34. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
Nagano N
Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
[TBL] [Abstract][Full Text] [Related]
35. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials.
Goodman WG
Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685
[TBL] [Abstract][Full Text] [Related]
36. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
Torres PA; De Broe M
Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism.
Sugimoto R; Watanabe H; Ikegami K; Enoki Y; Imafuku T; Sakaguchi Y; Murata M; Nishida K; Miyamura S; Ishima Y; Tanaka M; Matsushita K; Komaba H; Fukagawa M; Otagiri M; Maruyama T
Kidney Int; 2017 Mar; 91(3):658-670. PubMed ID: 27988213
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of Parsabiv
Harada K; Fujioka A; Konno M; Inoue A; Yamada H; Hirota Y
Eur J Pharmacol; 2019 Jan; 842():139-145. PubMed ID: 30342948
[TBL] [Abstract][Full Text] [Related]
39. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological regulation of parathyroid hormone secretion.
Nemeth EF
Curr Pharm Des; 2002; 8(23):2077-87. PubMed ID: 12171519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
